Company Description
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease.
It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus.
In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905.
The company has collaboration and license agreements with Brii Biosciences Limited, the National Research Council of Canada, and Coalition for Epidemic Preparedness Innovations.
The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016.
VBI Vaccines Inc. is based in Cambridge, Massachusetts.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 138 |
| CEO | Jeffery R. Baxter FCMA |
Contact Details
Address: 160 Second Street, Cambridge Cambridge, Massachusetts 02142 United States | |
| Phone | 617-830-3031 |
| Website | vbivaccines.com |
Stock Details
| Ticker Symbol | VBIV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000764195 |
| CUSIP Number | 91822J103 |
| ISIN Number | CA91822J2020 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeffery R. Baxter FCMA | President, Chief Executive Officer and Director |
| Dr. David Evander Anderson | Chief Scientific Officer |
| Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D. | Chief Medical Officer |
| Nell Beattie | Chief Financial Officer, Head of Corporate Development and Director |
| Nicole Anderson | Director of Corporate Communications and Investor Relations |
| Athena Kartsaklis | Senior Vice President of Finance, Chief Compliance Officer and Principal Financial Officer |
| Avi Mazaltov | Global Head of Manufacturing and GM of SciVac |
| Misha Nossov | Senior Vice President of Global Commercial Supply Strategy and Head of Europe |
| T. Adam Buckley | Senior Vice President of Business Development |
| John Robert Dillman | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2024 | 8-K | Current Report |
| May 29, 2024 | 8-K | Current Report |
| May 24, 2024 | 8-K | Current Report |
| May 15, 2024 | 8-K | Current Report |
| May 15, 2024 | 424B5 | Filing |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 1, 2024 | 8-K | Current Report |
| Apr 29, 2024 | ARS | Filing |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |